Compare Emerson Electric Co. (EMR) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Emerson Electric Co. vs BIO-TECHNE Corp — how do they compare? Emerson Electric Co. trades at $159.1 (market cap $88.81B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: Emerson Electric Co. is far larger — about 7.8× BIO-TECHNE Corp's market cap, and Emerson Electric Co. pays the higher dividend (1.39%). Which is the better fit depends on your goals — on Pluang, investors hold Emerson Electric Co. for 81 Days and BIO-TECHNE Corp for 63 Days on average.
| EMR | TECH | |
|---|---|---|
Market Cap | $88.81B | $11.37B |
Volume | 3,037,094 | 3,153,511 |
Sector | Industrials | Health |
52-Week High | $164.38 | $72.61 |
52-Week Low | $123.30 | $43.31 |
Typical Hold Time | 81 Days | 63 Days |
Enterprise Value | $99.89B | $11.40B |
Dividend Yield | 1.39% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Emerson Electric (EMR) trades at $159.06, down 1.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $165.90. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $1.84. Revenue and net income are projected to grow in 2026, supported by strong profitability margins including a 53.16% gross margin and 13.83% net margin.
The outlook for EMR is positive, with analyst sentiment leaning bullish (53.49% buy ratings) and technical indicators supporting upward momentum. Key risks include fluctuating cash flows and debt levels, while opportunities lie in continued earnings outperformance and solid fundamentals. The stock presents a favorable risk-reward profile near current levels.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Emerson Electric Co.
Emerson Electric is a multi-industrial conglomerate that operates under two business platforms: automation solutions and commercial and residential solutions. The latter is further subdivided into two operating segments: climate technologies, which sells HVAC and refrigeration products and services as well as tools and home products, which sells tools and compressors, among other products and services. Commercial and residential solutions boasts several household brands, including Copeland and RIDGID. Automation solutions is most known for its process manufacturing solutions, which consists of measurement instrumentation, as well as valves and actuators, among other products and services. Roughly half of the firm's geographic sales take place in the United States.
Read more on EMR →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
